DUBLIN–(BUSINESS WIRE)–The “Monoclonal Antibodies (mAbs) Global Market Report 2020” report has been added to ResearchAndMarkets.com’s offering.
The global monoclonal antibodies (mAbs) market was valued at about $135.38 billion in 2018 and is expected to grow to $212.64 billion at a CAGR of 12.0% through 2022.
The monoclonal antibodies (mAbs) market consists of sales of monoclonal antibodies and related services. Monoclonal antibodies are used to enhance and suppress immune response in various medical conditions and to treat various diseases such as cancer, cardiovascular and cerebrovascular diseases. This industry includes establishments that produce anti-cancer monoclonal antibodies to prevent metastasis by reducing cell proliferation, immunological monoclonal anti-bodies, neuropharmacological monoclonal anti-bodies, anti-infective monoclonal antibodies (mAbs) and other mAbs for human beings and animals.
North America was the largest region in the monoclonal antibodies market. In 2018, followed by Europe, Asia Pacific and Middle East respectively. This region is expected to remain the largest during the next five years. The monoclonal antibodies market in Middle East is forecasted to register the highest CAGR during 2018-2023.
Increasing prevalence of cost efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce cost of medication and increase access to treatment. Biosimilar are the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.
Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue of US retail sales of homeopathic and herbal remedies was around $7.5 billion in 2017. Similarly, traditional and complementary medicine market increased from $199 billion in 2015 to $360 billion in 2017. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure and limiting the demand for monoclonal antibody drugs.
The monoclonal antibodies market has been witnessing multiple strategic initiatives in the recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into multi-target partnership to create an antibody drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases.
Furthermore, in 2017, AbCellera collaborated with GlaxoSmithKline (GSK), a pharmaceutical company, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In November 2015, Merck completed the acquisition of Sigma-Aldrich Corp., a leading life science company. Post this acquisition, Merck has more than 50,000 employees, 72 manufacturing sites, and presence in 67 countries worldwide.
Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally
The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by USFDA is expected to support the monoclonal antibody therapeutics market growth.
For instance, in 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, in 2017, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (mUC).
Major players in the market are Johnson & Johnson, Merck, AbbVie, Amgen, Glaxosmithkline plc
- Markets Covered: 1) By Source: Murine, Chimeric, Humanized, Human 2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (mAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Others 3) By End Users: Hospitals, Private Clinics, Research Institute
- Companies Mentioned: Johnson & Johnson, Merck, AbbVie, Amgen, Glaxosmithkline plc
- Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
- Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
- Time Series: Five years historic and forecast.
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Norvatis AG
- Pfizer Inc
- Thermofischer Scientific
- Elililly and Company
- Bristol-Myers Squibb
- Hoffman Roche Ltd
- Abbott Laboratories
- Mylan N.V
- Novo Nordisk A/S
- Daiichi Sankyo Company ltd.
- Seattle genetics
- Teva pharmaceutical industries
- Shanghi Junsi bioscience ltd
- Sigma-Aldrich Co. LLC
- ADC Therapeutics
- Alexion Pharmaceuticals
- ALMAC Group
- Astellas Pharma
- Celldex Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/e9tkbm
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900